Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Asset Writedowns and Impairment (2022 - 2025)

Historic Asset Writedowns and Impairment for InMed Pharmaceuticals (INM) over the last 4 years, with Q4 2025 value amounting to $70000.0.

  • InMed Pharmaceuticals' Asset Writedowns and Impairment changed N/A to $70000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $112408.0, marking a year-over-year change of. This contributed to the annual value of $2424.0 for FY2025, which is 9920.74% down from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Asset Writedowns and Impairment of $70000.0 as of Q4 2025.
  • InMed Pharmaceuticals' Asset Writedowns and Impairment's 5-year high stood at $576772.0 during Q3 2022, with a 5-year trough of -$267835.0 in Q2 2023.
  • Its 4-year average for Asset Writedowns and Impairment is $114124.8, with a median of $81465.0 in 2023.
  • In the last 5 years, InMed Pharmaceuticals' Asset Writedowns and Impairment crashed by 8388.79% in 2023 and then surged by 11583.36% in 2024.
  • InMed Pharmaceuticals' Asset Writedowns and Impairment (Quarter) stood at $576772.0 in 2022, then tumbled by 70.44% to $170474.0 in 2023, then tumbled by 75.12% to $42408.0 in 2024, then surged by 65.06% to $70000.0 in 2025.
  • Its last three reported values are $70000.0 in Q4 2025, $42408.0 for Q2 2024, and $170474.0 during Q4 2023.